These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 9854499)

  • 1. Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients.
    Cavaletti G; Bogliun G; Zincone A; Marzorati L; Melzi P; Frattola L; Marzola M; Bonazzi C; Cantù MG; Chiari S; Galli A; Bregni M; Gianni MA
    Anticancer Res; 1998; 18(5B):3797-802. PubMed ID: 9854499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
    Möbus V; Wandt H; Frickhofen N; Bengala C; Champion K; Kimmig R; Ostermann H; Hinke A; Ledermann JA; ;
    J Clin Oncol; 2007 Sep; 25(27):4187-93. PubMed ID: 17698804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J
    Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safe and effective administration of carboplatin-based chemotherapy in a patient undergoing hemodialysis with cancer of unknown primary by monitoring observed AUC of carboplatin-a case report].
    Kondo M; Kuroda J; Ikai Y; Hayashi R; Uegaki S; Yoshida T; Yoshida A; Komatsu H; Kimura K
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1749-52. PubMed ID: 23152033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.
    Sehouli J; Stengel D; Elling D; Ortmann O; Blohmer J; Riess H; Lichtenegger W;
    Gynecol Oncol; 2002 May; 85(2):321-6. PubMed ID: 11972395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
    Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
    Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer.
    Wandt H; Birkmann J; Denzel T; Schäfer K; Schwab G; Pilz D; Egger H; Both A; Gallmeier WM
    Bone Marrow Transplant; 1999 Apr; 23(8):763-70. PubMed ID: 10231137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
    Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
    Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety evaluation of adjuvant chemotherapy by weekly paclitaxel combined with weekly carboplatin in patients with postoperative non-small cell lung cancer].
    Hirose T; Nagao T; Kajikawa A; Sumi T; Sugimoto T; Hirose Y; Yoshida M; Kenzaki K
    Gan To Kagaku Ryoho; 2007 Sep; 34(9):1397-400. PubMed ID: 17876136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
    Morgan RJ; Synold TW; Gandara D; Muggia F; Scudder S; Reed E; Margolin K; Raschko J; Leong L; Shibata S; Tetef M; Vasilev S; McGonigle K; Longmate J; Yen Y; Chow W; Somlo G; Carroll M; Doroshow JH
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):283-9. PubMed ID: 15184995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
    Donadio C; Lucchesi A; Ardini M; Cosio S; Fanucchi A; Gadducci A
    Ther Drug Monit; 2009 Feb; 31(1):63-9. PubMed ID: 19077927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
    Montaguti M; Brandolini C; Ferri GG; Hatzopoulos S; Prete A; Pession A
    Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma.
    Jehanne M; Lumbroso-Le Rouic L; Savignoni A; Aerts I; Mercier G; Bours D; Desjardins L; Doz F
    Pediatr Blood Cancer; 2009 May; 52(5):637-43. PubMed ID: 19148943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Carboplatin in cancer of the ovary].
    Pujade-Lauraine E; Guastalla JP; Vincent P
    Bull Cancer; 2000 Aug; 87 Spec No():40-7. PubMed ID: 11082722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.
    Dizon DS; Sabbatini PJ; Aghajanian C; Hensley ML; Spriggs DR
    Gynecol Oncol; 2002 Mar; 84(3):378-82. PubMed ID: 11855873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined chemotherapy with weekly paclitaxel and carboplatin for recurrent and refractory epithelial ovarian cancer--phase I study].
    Misawa A; Yasuda M
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1445-52. PubMed ID: 17033235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
    Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
    Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic isolated regional perfusion of the limb with carboplatin.
    Daryanani D; de Vries EG; Guchelaar HJ; van Weerden TW; Hoekstra HJ
    Eur J Surg Oncol; 2000 Dec; 26(8):792-7. PubMed ID: 11087648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.